Asensus Surgical Inc

Asensus Surgical — Transenterix — JP Morgan Healthcare Conference 2018

22 slides from Asensus Surgical's conference presentation, Jan 8, 2018

  1. Slide 1: TransEnterix

    Slide 1: TransEnterix

    \ Exhibit 99.1 Fenctnterix:

  2. Slide 2: JP Morgan Healthcare Conference, Todd M. Pope

    Slide 2: JP Morgan Healthcare Conference, Todd M. Pope

    Todd M. Pope President & CEO JP Morgan Healthcare Conference January 8, 2018

  3. Slide 3: Forward Looking Statements

    Slide 3: Forward Looking Statements

    Forward Looking Statements This presentation includes statements relating to TransEnterix’s current regulatory and commercialization plans for our products, the Senhance™ Surgical Robotic System and the SurgiBot™ System. These statements and other statements regarding our future plans and goals cons

  4. Slide 4: Commercial Stage Surgical Robotics Company

    Slide 4: Commercial Stage Surgical Robotics Company

    Commercial Stage Clinically validated in multiple procedures and sites Senhance FDA cleared and CE Marked Sales and distribution in place in US and EU Strong financial position Compelling Platform Technology Senhance Surgical Robot Robotic benefits with responsible economics Focus: Surgical Robotics

  5. Slide 5: Value-based healthcare is forcing hospitals to find new ways

    Slide 5: Value-based healthcare is forcing hospitals to find new ways

    Value-based healthcare is forcing hospitals to find new ways to improve outcomes, efficiencies and talent retention.

  6. Slide 6: Surgical Robotics Poised for Growth

    Slide 6: Surgical Robotics Poised for Growth

    Surgical Robotics Poised for Growth in 2023 in 2017 Robotic surgery is <10% of surgery today Largest opportunity is to convert laparoscopic procedures; not enabled by current options Must meet value-based healthcare criteria and build off laparoscopy (>60% of surgery) Source: Abdominal Surgical Robo

  7. Slide 7: Robotic Surgery Landscape

    Slide 7: Robotic Surgery Landscape

    Robotic Surgery Landscape 0.7 MM procedures EU & U.S. Historical Growth Drivers: Convert open surgeries to robotics Offset signficant per-procedure cost increase with length of stay benefit vs. open surgery Clinical and patient benefits have come from converting an open procedure to a minimally-inva

  8. Slide 8: Future Growth Drivers: Convert laparoscopic surgeries to robotics

    Slide 8: Future Growth Drivers: Convert laparoscopic surgeries to robotics

    Future Growth Drivers: Convert laparoscopic surgeries to robotics Improve laparoscopy: designed for greater precision, efficiencies, safety, ergonomics Provide meaningful robotic benefits to laparoscopic surgery without significant per procedure cost increase Sources: TRXC Estimates and Millennium R

  9. Slide 9: Need for Robotic System that Addresses the Laparoscopic Market

    Slide 9: Need for Robotic System that Addresses the Laparoscopic Market

    Need for Robotic System that Addresses the Laparoscopic Market Familiar motion and approach Completed learning curve Significant investments in laparoscopic ecosystem Laparoscopy is Widespread Limitations of Laparoscopy Reliance on assistant to control camera Challenging ergonomics Imprecise instrum

  10. Slide 10: Senhance is Uniquely Positioned to Address Laparoscopic Market

    Slide 10: Senhance is Uniquely Positioned to Address Laparoscopic Market

    Senhance is Uniquely Positioned to Address Laparoscopic Market Senhance Robotic Benefits Precision Ergonomics Advanced Instrument-ation Eye- sensing camera control

  11. Slide 11: Senhance Surgery

    Slide 11: Senhance Surgery

    ©» SsenhanceSurgery a: am

  12. Slide 12: Growing TransEnterix Patent Portfolio

    Slide 12: Growing TransEnterix Patent Portfolio

    Growing TransEnterix Patent Portfolio Issued Patents: 93 worldwide Includes 25 US issued Patent Applications: 92 worldwide Includes 54 pending US applications

  13. Slide 13: Building Clinical Validation

    Slide 13: Building Clinical Validation

    Building Clinical Validation Imperial College, St. Mary’s, London, England C.H.U. ST Etienne, Saint-Etienne, France St. Marien-Krankenhaus, Siegen, Germany University Clinic Hamburg – Eppendorf (UKE), Hamburg, Germany Humanitas University, Milan, Italy Policlinico Gemelli, Rome, Italy Saitama Medica

  14. Slide 14: Senhance Robotic Inguinal Hernia Repair

    Slide 14: Senhance Robotic Inguinal Hernia Repair

    Senhance Robotic Inguinal Hernia Repair Left side, TAPP, Lateral and Medial Hernias Dr. Dietmar Stephan, St. Marien Krankenhaus Siegen, Germany Department of Minimally Invasive and Robotic Surgery Clinic of General Surgery, Chief Prof. Dr. F. Willeke

  15. Slide 15: Senhance FDA Cleared and CE Marked

    Slide 15: Senhance FDA Cleared and CE Marked

    Senhance FDA Cleared and CE Marked First new entrant to abdominal robotics since 2000 Senhance received FDA clearance October 2017 Cleared for colorectal and gynecological laparoscopic surgery in US Indications cover 23 procedures Covers benign and oncologic treatments Initial market 1.5 million US

  16. Slide 16: Delivering on Open Architecture Strategy

    Slide 16: Delivering on Open Architecture Strategy

    Delivering on Open Architecture Strategy Robotic Microlap Open Source Visualization Introducing the first robotic microlap 3mm system Enabling virtually scarless surgery Using robotic precision, tremor filtration and surgeon camera control with microlaparoscopy Leverage existing hospital visualizati

  17. Slide 17: Articulating Instrumentation and platform expansions

    Slide 17: Articulating Instrumentation and platform expansions

    Articulating Instrumen n platform expans ons for use ons | 4 | Based on ultrasonic energy Clinically and financially validated need: $2+ billion global business in surgical advanced energy instruments Increase degrees of freedom in surgical cases Minimize incision size with 5mm platform Source: Medt

  18. Slide 18: Commercial Activity - US

    Slide 18: Commercial Activity - US

    Commercial Activity - US Sales resources 17 sales professionals Majority of 20 largest MSAs covered Established surgeon training center at the Institute for Surgical Advancement in Orlando Q3 ’17 Strong presence at major trade shows Sales activities First sale to Florida Hospital Orlando Q4 ’17 Anti

  19. Slide 19: Commercial Activity - OUS

    Slide 19: Commercial Activity - OUS

    Commercial Activity - OUS Strong foundation established Direct sales team covering Germany, Italy, France, Benelux & UK Distributors and agents expand coverage to other markets Sales activities Italian sale Q3 ’16 German sale in Q1 ’17 Japan sale Q2 ’17 Taiwan sale Q3 ’17 CIS sale Q4 ‘17

  20. Slide 20: SurgiBot Commercialization Update/Strategy

    Slide 20: SurgiBot Commercialization Update/Strategy

    SurgiBot Commercialization Update/Strategy Enables TransEnterix to expand portfolio, increases cash, and develops partner relationship for China manufacturing and distribution Received minimum consideration of $29 million (cash, stock purchase and royalties) Retain rights for distribution and sales

  21. Slide 21: Financial (unaudited)

    Slide 21: Financial (unaudited)

    Financial (unaudited) 2017 Revenue ~ $7.0 million 360% increase over 2016 December 31, 2017 Balance Sheet Highlights Cash & Restricted Cash ~ $97 million Debt ~ $14 million Common shares outstanding ~ 199 million

  22. Slide 22: Key Priorities

    Slide 22: Key Priorities

    Key Priorities 2017 Continued focus on commercialization efforts in CE Mark countries ✓ Continue to demonstrate clinical success across multiple specialties and procedures ✓ Obtain Senhance US 510(k) clearance by year end ✓ Prepare for U.S. launch with focused market development activities ✓ 2018 Co

Source: SEC EDGAR · 8-K filed Jan 8, 2018

More decks from Asensus Surgical Inc